ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SCYX Scynexis Inc

1.80
0.07 (4.05%)
After Hours
Last Updated: 23:44:35
Delayed by 15 minutes
Share Name Share Symbol Market Type
Scynexis Inc NASDAQ:SCYX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.07 4.05% 1.80 1.81 1.83 1.92 1.725 1.73 219,519 23:44:35

SCYNEXIS to Present at Upcoming Investor Conferences

31/08/2017 2:05pm

GlobeNewswire Inc.


Scynexis (NASDAQ:SCYX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Scynexis Charts.

SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the following upcoming investor conferences:

  • Baird’s 2017 Global Healthcare Conference at the InterContinental New York Barclay Hotel on Thursday, September 7, 2017 at 8:30 a.m. ET.
  • The Rodman & Renshaw 19th Annual Global Investment Conference at the Lotte New York Palace Hotel on Monday, September 11, 2017 at 9:35 a.m. ET.
  • The Cantor Fitzgerald 2017 Global Healthcare Conference at the InterContinental New York Barclay Hotel on Wednesday, September 27, 2017 at 11:30 a.m. ET.

Live webcasts of each presentation will be available on the investors section of the Company’s website: www.SCYNEXIS.com. Replays of each presentation will be available approximately two hours after each event and will be available for two weeks following each presentation.

About SCYNEXISSCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is the first representative of a novel intravenous and oral triterpenoid antifungal family and is in Phase 2 clinical development for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections.  For more information, visit www.scynexis.com.

CONTACT: 

Media Relations
Cammy Duong
MacDougall Biomedical Communications
Tel: 781-591-3443
cduong@macbiocom.com

Investor Relations
Susan Kim
Argot Partners
Tel: 212-203-4433
susan@argotpartners.com

1 Year Scynexis Chart

1 Year Scynexis Chart

1 Month Scynexis Chart

1 Month Scynexis Chart

Your Recent History

Delayed Upgrade Clock